These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32267185)

  • 21. Idarucizumab for dabigatran reversal in daily clinical practice: A case series.
    Vene N; Mavri A; Božič-Mijovski M; Gregorič M; Uštar KK; Žerjav U; Gradišek P; Stecher A; Frol S; Nedog V; Detkova N; Kosi IE
    Eur J Anaesthesiol; 2020 Oct; 37(10):874-878. PubMed ID: 32175987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.
    Edwards G; Roman C; Jithoo R; Mitra B
    Trauma Case Rep; 2018 Feb; 13():46-49. PubMed ID: 29644298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of Dabigatran Bleeding and Coagulopathy Using Idarucizumab in a Patient With Acute Kidney Injury.
    Vidal J; DePalma R; Forouzan L
    P T; 2018 Dec; 43(12):748-749. PubMed ID: 30559587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M
    Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
    Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis.
    Fuhr LM; Hanke N; Meibohm B; Lehr T
    Clin Pharmacokinet; 2020 Jun; 59(6):809-825. PubMed ID: 32020532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
    Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
    Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
    Lu VM; Phan K; Rao PJ; Sharma SV; Kasper EM
    Clin Neurol Neurosurg; 2019 Jun; 181():76-81. PubMed ID: 31015061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
    Stangier J; Stähle H; Rathgen K; Fuhr R
    Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.